Update information
February 2025: Recommendations in the section on lymphoedema (recommendations 1.5.1 to 1.5.7) have been stood down as they have been superseded by the update on lymphoedema early identification, risk reduction and management in the NICE guideline on early and locally advanced breast cancer: diagnosis and management.
August 2017: We reviewed the evidence and updated recommendations in section 1.1 on assessing oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status on disease recurrence.
July 2014: We reviewed the evidence on exercise for people with or at risk of lymphoedema and added 2 recommendations to section 1.5.
Recommendations are marked as [2017], [2014] or [2009].
[2017] indicates that the evidence was reviewed and the recommendation updated in 2017.
[2014] indicates that the evidence was reviewed and the recommendation added in 2014.
[2009] indicates that the evidence was reviewed in 2009.
ISBN: 978-1-4731-6858-9